These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 28507476)

  • 1. Effect of clopidogrel on the hydroxylation and sulfoxidation of omeprazole: A single dose study in healthy human volunteers.
    Ahmad L; Iqbal Z; Nazir S; Khan A; Shah Y; Khan MI; Khan I; Khan A
    EXCLI J; 2017; 16():321-327. PubMed ID: 28507476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative pharmacokinetics of Omeprazole and its metabolites in poor and extensive metabolizer Pakistani healthy volunteers and a review of different studies.
    Ahmad L; Iqbal Z; Shah Y; Nazir S; Khan A; Khan MI; Khan A; Khuda F; Khan I
    Pak J Pharm Sci; 2018 Jul; 31(4):1363-1374. PubMed ID: 30033421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin.
    Böttiger Y; Tybring G; Götharson E; Bertilsson L
    Clin Pharmacol Ther; 1997 Oct; 62(4):384-91. PubMed ID: 9357389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clopidogrel inhibits CYP2C19-dependent hydroxylation of omeprazole related to CYP2C19 genetic polymorphisms.
    Chen BL; Chen Y; Tu JH; Li YL; Zhang W; Li Q; Fan L; Tan ZR; Hu DL; Wang D; Wang LS; Ouyang DS; Zhou HH
    J Clin Pharmacol; 2009 May; 49(5):574-81. PubMed ID: 19398604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. St John's wort induces both cytochrome P450 3A4-catalyzed sulfoxidation and 2C19-dependent hydroxylation of omeprazole.
    Wang LS; Zhou G; Zhu B; Wu J; Wang JG; Abd El-Aty AM; Li T; Liu J; Yang TL; Wang D; Zhong XY; Zhou HH
    Clin Pharmacol Ther; 2004 Mar; 75(3):191-7. PubMed ID: 15001970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Omeprazole hydroxylation is inhibited by a single dose of moclobemide in homozygotic EM genotype for CYP2C19.
    Cho JY; Yu KS; Jang IJ; Yang BH; Shin SG; Yim DS
    Br J Clin Pharmacol; 2002 Apr; 53(4):393-7. PubMed ID: 11966672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of rabeprazole on the antiplatelet effects and pharmacokinetics of clopidogrel in healthy volunteers.
    Funck-Brentano C; Szymezak J; Steichen O; Ducint D; Molimard M; Remones V; Azizi M; Gaussem P
    Arch Cardiovasc Dis; 2013 Dec; 106(12):661-71. PubMed ID: 24246616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Herbal medicine yin zhi huang induces CYP3A4-mediated sulfoxidation and CYP2C19-dependent hydroxylation of omeprazole.
    Fan L; Wang G; Wang LS; Chen Y; Zhang W; Huang YF; Huang RX; Hu DL; Wang D; Zhou HH
    Acta Pharmacol Sin; 2007 Oct; 28(10):1685-92. PubMed ID: 17883958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Steady-state pharmacokinetics of once-daily fosamprenavir/ritonavir and atazanavir/ritonavir alone and in combination with 20 mg omeprazole in healthy volunteers.
    Luber AD; Brower R; Kim D; Silverman R; Peloquin CA; Frank I
    HIV Med; 2007 Oct; 8(7):457-64. PubMed ID: 17760738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of cytochrome P2C19 in R-warfarin pharmacokinetics and its interaction with omeprazole.
    Uno T; Sugimoto K; Sugawara K; Tateishi T
    Ther Drug Monit; 2008 Jun; 30(3):276-81. PubMed ID: 18520598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the interaction potential of a new proton pump inhibitor, E3810, versus omeprazole with diazepam in extensive and poor metabolizers of S-mephenytoin 4'-hydroxylation.
    Ishizaki T; Chiba K; Manabe K; Koyama E; Hayashi M; Yasuda S; Horai Y; Tomono Y; Yamato C; Toyoki T
    Clin Pharmacol Ther; 1995 Aug; 58(2):155-64. PubMed ID: 7648765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S-mephenytoin 4'-hydroxylation status.
    Yasuda S; Horai Y; Tomono Y; Nakai H; Yamato C; Manabe K; Kobayashi K; Chiba K; Ishizaki T
    Clin Pharmacol Ther; 1995 Aug; 58(2):143-54. PubMed ID: 7648764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decreased plasma exposure of clopidogrel active metabolite in rats after long-term treatment with clopidogrel.
    Wang Y; Liu Y; Yao H; Chen X; Sun Y; Guo Y
    Biopharm Drug Dispos; 2023 Apr; 44(2):129-136. PubMed ID: 36905582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single and multiple dose pharmacokinetics of nefazodone in subjects classified as extensive and poor metabolizers of dextromethorphan.
    Barbhaiya RH; Buch AB; Greene DS
    Br J Clin Pharmacol; 1996 Nov; 42(5):573-81. PubMed ID: 8951188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 5-hydroxylation of omeprazole by human liver microsomal fractions from Chinese populations related to CYP2C19 gene dose and individual ethnicity.
    Shu Y; Wang LS; Xu ZH; He N; Xiao WM; Wang W; Huang SL; Zhou HH
    J Pharmacol Exp Ther; 2000 Nov; 295(2):844-51. PubMed ID: 11046127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disposition kinetics and metabolism of omeprazole in extensive and poor metabolizers of S-mephenytoin 4'-hydroxylation recruited from an Oriental population.
    Sohn DR; Kobayashi K; Chiba K; Lee KH; Shin SG; Ishizaki T
    J Pharmacol Exp Ther; 1992 Sep; 262(3):1195-202. PubMed ID: 1527724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enantioselective hydroxylation of omeprazole catalyzed by CYP2C19 in Swedish white subjects.
    Tybring G; Böttiger Y; Widén J; Bertilsson L
    Clin Pharmacol Ther; 1997 Aug; 62(2):129-37. PubMed ID: 9284848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Absolute bioavailability and metabolism of omeprazole in relation to CYP2C19 genotypes following single intravenous and oral administrations.
    Uno T; Niioka T; Hayakari M; Yasui-Furukori N; Sugawara K; Tateishi T
    Eur J Clin Pharmacol; 2007 Feb; 63(2):143-9. PubMed ID: 17203292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of omeprazole on the pharmacokinetics of moclobemide according to the genetic polymorphism of CYP2C19.
    Yu KS; Yim DS; Cho JY; Park SS; Park JY; Lee KH; Jang IJ; Yi SY; Bae KS; Shin SG
    Clin Pharmacol Ther; 2001 Apr; 69(4):266-73. PubMed ID: 11309556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regioselective hydroxylation of omeprazole enantiomers by bacterial CYP102A1 mutants.
    Ryu SH; Park BY; Kim SY; Park SH; Jung HJ; Park M; Park KD; Ahn T; Kang HS; Yun CH
    Drug Metab Dispos; 2014 Sep; 42(9):1493-7. PubMed ID: 25008345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.